Open Access

Andreas Wollenberg, Antonio Costanzo, Christian Vestergaard, Koji Masuda, Katarzyna Morawska, Burcu Vardar, Hitendra Pandey, Silvia Sabatino, Jose-Manuel Carrascosa

• Objective: To report response maintenance in patients with moderate-to-severe Atopic Dermatitis (AD) upon continuous or downtitrated baricitinib treatment for 200 weeks. Methods: Patients with vIGA-AD® (validated Investigator Global Assessment for Atopic Dermatitis) score ≤2 at Week 52 treated with baricitinib 4 mg were re-randomized (1:1:1) to continue (4 mg), down-titrate (2 mg) or dose withdrawal (placebo). Response to continuous and downtitrated treatment was assessed from Week 52 to 200 in the overall substudy population (vIGA-AD 0,1,2) and in substudy patients with higher response (vIGA-AD 0,1) at Week 52. Results: Efficacy was maintained in Week 52 responders (vIGA-AD 0,1,2) continuing baricitinib 4 mg, as measured by vIGA-AD (0,1) (Week 52 [51.2%], Week 200 [51.2%]); Eczema Area and Severity Index (EASI) 75 (Week 52 [82.1%], Week 200 [79.8%]). Patients with vIGA-AD (0,1) at Week 52 maintained higher response rates during continued treatment and after down-titration comparedObjective: To report response maintenance in patients with moderate-to-severe Atopic Dermatitis (AD) upon continuous or downtitrated baricitinib treatment for 200 weeks. Methods: Patients with vIGA-AD® (validated Investigator Global Assessment for Atopic Dermatitis) score ≤2 at Week 52 treated with baricitinib 4 mg were re-randomized (1:1:1) to continue (4 mg), down-titrate (2 mg) or dose withdrawal (placebo). Response to continuous and downtitrated treatment was assessed from Week 52 to 200 in the overall substudy population (vIGA-AD 0,1,2) and in substudy patients with higher response (vIGA-AD 0,1) at Week 52. Results: Efficacy was maintained in Week 52 responders (vIGA-AD 0,1,2) continuing baricitinib 4 mg, as measured by vIGA-AD (0,1) (Week 52 [51.2%], Week 200 [51.2%]); Eczema Area and Severity Index (EASI) 75 (Week 52 [82.1%], Week 200 [79.8%]). Patients with vIGA-AD (0,1) at Week 52 maintained higher response rates during continued treatment and after down-titration compared with overall substudy population. Conclusion: AD symptom improvement was maintained up to Week 200 with baricitinib 4 mg. After down-titration, the vIGA-AD (0,1) response patient subgroup maintained clear or almost clear skin and itch response improvement. Clear or almost clear skin achievement may help identify optimal candidates for down-titration after 52 weeks of full-dose treatment.…